Effect of Low Molecular Weight Heparin Combined with Benzabate in the Treatment of Hyperlipidemic Acute Pancreatitis
Objective To observe the effect of low molecular weight heparin combined with benzabate in the treatment of hyperlipidemic acute pancreatitis(HLAP).Methods A total of 80 patients with HLAP treated in the First Affiliated Hospital of Xinxiang Medical College from October 2022 to October 2023 were selected and divided into two groups by random number table method.The control group received symptomatic treatment such as fasting,nutritional support,anti-infection,inhibition of pancreatic enzyme secretion.The observation group was given low molecular weight heparin combined with benzabate on the basis of symptomatic treatment.The clinical effect of the two groups was compared.Results The recovery time of intestinal sound,relief time of abdominal distension and abdominal pain,disappearance time of peritonitis signs and hospitalization time in the observation group were shorter than those in the control group,with statistical significance(P＜0.05).After treatment,triglyceride,free fatty acid,blood amylase,urine amylase,lipase,apolipoprotein B and coagulation function indexes in 2 groups were lower than before treatment,and the observation group were lower than the control group,the difference was statistically significant(P＜0.05).The incidence of multiple organ dysfunction syndrome(MODS)in the observation group was lower than that in the control group,and there was no significant difference in ICU admission rate and 28 days mortality between the observation group and the control group(P＞0.05).Conclusion Low molecular weight heparin combined with benzabate in the treatment of HLAP can regulate lipid metabolism,reduce hematuric amylase,improve coagulation function and reduce the occurrence of MODS.
low molecular weight heparinbenzabatehyperlipidemic acute pancreatitislipid metabolismcoagulation function
万方数据
维普
